Drug Profile
Research programme: Alzheimer's disease therapeutics - Selonterra
Latest Information Update: 10 Mar 2023
Price :
$50
*
At a glance
- Originator Selonterra
- Class Antidementias; Small molecules
- Mechanism of Action Apolipoprotein E4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease
Highest Development Phases
- Research Alzheimer's disease
Most Recent Events
- 10 Mar 2023 Early research is still ongoing in Alzheimer's disease in USA (Selonterra website, March 2023)
- 28 Feb 2021 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 16 Jun 2020 Selonterra collaborates with Axxam to identify small molecule therapies for Alzheimer’s disease